Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience

BACKGROUND: Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy have yet to be reported. AIM: This retrospective clinical study aimed to elucidate early responses to Atez/Bev. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Iijima, Hiroko, Hiasa, Yoichi, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842687/
https://www.ncbi.nlm.nih.gov/pubmed/34114752
http://dx.doi.org/10.1002/cnr2.1464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842687/
https://www.ncbi.nlm.nih.gov/pubmed/34114752
http://dx.doi.org/10.1002/cnr2.1464

Ejemplares similares